Argo Wealth Advisory LLC Acquires New Holdings in Stryker Corporation $SYK

Key Points

• Argo Wealth Advisory acquired 7,618 shares of Stryker in Q4 worth about $2.68 million, representing roughly 1.6% of its portfolio and the stock's 20th largest holding.
• Director Ronda E. Stryker sold 250,000 shares on Feb. 4 at an average $362.92 (~$90.73 million), trimming her position by 9.23%; insiders still own about 4.60% of the company.
• Analyst and company update: Stryker beat Q4 EPS and revenue estimates with 11.4% revenue growth, carries a consensus "Moderate Buy" (average target $421.11), and declared a $0.88 quarterly dividend (1.0% yield).

Argo Wealth Advisory LLC acquired a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 7,618 shares of the medical technology company's stock, valued at approximately $2,678,000. Stryker accounts for about 1.6% of Argo Wealth Advisory LLC's investment portfolio, making the stock its 20th biggest holding.

Other large investors have also recently bought and sold shares of the company. Clayton Financial Group LLC bought a new stake in shares of Stryker during the 3rd quarter worth approximately $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC bought a new position in Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker during the 3rd quarter worth $34,000. Finally, Copia Wealth Management grew its holdings in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock worth $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Analyst Ratings Changes

SYK has been the topic of several analyst reports. Needham & Company LLC increased their target price on Stryker from $448.00 to $454.00 and gave the stock a "buy" rating in a report on Friday, January 30th. Piper Sandler reiterated an "overweight" rating on shares of Stryker in a research report on Tuesday, January 27th. Citizens Jmp upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $440.00 price objective for the company in a research report on Friday, December 19th. William Blair restated an "outperform" rating on shares of Stryker in a research report on Thursday, March 5th. Finally, Raymond James Financial upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 target price for the company in a report on Tuesday, January 6th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $421.11.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.60% of the company's stock.

Stryker Stock Performance

Shares of SYK opened at $337.76 on Friday. The firm has a market cap of $129.36 billion, a PE ratio of 40.21, a PEG ratio of 1.99 and a beta of 0.92. The stock's fifty day moving average price is $353.28 and its two-hundred day moving average price is $359.79. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 1 year low of $319.32 and a 1 year high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $4.01 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio (DPR) is 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.